Deals in Depth: September 2008
September 2008 dealmaking highlights: Medivation landed a potential $725mm through its deal with Pfizer for AD/Huntington's candidate Dimebon. In top M&As, Japanese firm Shionogi acquired US-based Sciele for $1.4bn and Getinge paid $841mm for fellow CV-focused Datascope. Compared with September, FOPO money into biopharma almost doubled thanks to Vertex's $218mm offering, while on the device side no follow-ons were completed and private financing decreased about $100mm.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.